Breathe BioMedical Inc. is a medical technology company. It is focused on developing a breath test to be used as an adjunctive test to mammography screening to detect early-stage breast cancer in women with dense breast tissue. Breath analytics involves the collection, processing, and analysis of breath samples to identify biomarker patterns associated with specific diseases. It is developing a proprietary end-to-end breath analytics platform, the intended use of which is to enable breath testing for the detection of disease. Its platform technology combines three advanced technologies to sample, digitize and analyze breath with the potential to detect multiple diseases. Its spectrometer technology uses Cavity Ring-Down Spectroscopy (CRDS) to measure the volatile organic compounds (VOCs) in breath samples which are collected using its breath sampler device (SohnoXB). Spectrometer is designed to be very fast, permitting sample analysis down to parts-per-trillion levels.
Ticker SymbolBRTH
Company nameBreathe BioMedical Inc
IPO date- -
CEODawes (William)
Number of employees- -
Security typeOrdinary Share
Fiscal year-end- -
Address191 Halifax Street
CityMONCTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeE1C 9R7
Phone19024148148
Websitehttps://breathebiomedical.com/
Ticker SymbolBRTH
IPO date- -
CEODawes (William)
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data